BR0211827A - Uso de inibidores de il-18 em distúrbios de hipersensibilidade - Google Patents

Uso de inibidores de il-18 em distúrbios de hipersensibilidade

Info

Publication number
BR0211827A
BR0211827A BR0211827-0A BR0211827A BR0211827A BR 0211827 A BR0211827 A BR 0211827A BR 0211827 A BR0211827 A BR 0211827A BR 0211827 A BR0211827 A BR 0211827A
Authority
BR
Brazil
Prior art keywords
inhibitors
hypersensitivity disorders
hypersensitivity
disorders
medicament
Prior art date
Application number
BR0211827-0A
Other languages
English (en)
Other versions
BRPI0211827B8 (pt
BRPI0211827B1 (pt
Inventor
Yolande Chvatchko
Marie Kosco-Vilbois
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of BR0211827A publication Critical patent/BR0211827A/pt
Publication of BRPI0211827B1 publication Critical patent/BRPI0211827B1/pt
Publication of BRPI0211827B8 publication Critical patent/BRPI0211827B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"USO DE INIBIDORES DE IL-18 EM DISTúRBIOS DE HIPERSENSIBILIDADE". A invenção refere-se ao uso de inibidores de IL-18 na preparação de um medicamento para o tratamento e/ou prevenção de distúrbios de hipersensibilidade e em particular de hipersensibilidade do tipo tardia.
BR0211827A 2001-08-10 2002-08-01 uso de proteína de ligação a il-18 (il-18bp) para fabricação de um medicamento para tratamento e/ou prevenção de um distúrbio de hipersensibilidade do tipo iv BRPI0211827B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01118811.7 2001-08-10
EP01118811 2001-08-10
EP02100735.6 2002-06-20
EP02100735 2002-06-20
PCT/EP2002/008591 WO2003013577A2 (en) 2001-08-10 2002-08-01 Use of il-18 inhibitors in hypersensitivity disorders

Publications (3)

Publication Number Publication Date
BR0211827A true BR0211827A (pt) 2004-08-31
BRPI0211827B1 BRPI0211827B1 (pt) 2019-07-23
BRPI0211827B8 BRPI0211827B8 (pt) 2021-05-25

Family

ID=26076673

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211827A BRPI0211827B8 (pt) 2001-08-10 2002-08-01 uso de proteína de ligação a il-18 (il-18bp) para fabricação de um medicamento para tratamento e/ou prevenção de um distúrbio de hipersensibilidade do tipo iv

Country Status (27)

Country Link
US (1) US20040247598A1 (pt)
EP (1) EP1423138B1 (pt)
JP (1) JP4301942B2 (pt)
KR (1) KR20040030948A (pt)
CN (1) CN100500210C (pt)
AR (1) AR035274A1 (pt)
AU (1) AU2002331376B2 (pt)
BR (1) BRPI0211827B8 (pt)
CA (1) CA2456247C (pt)
CY (1) CY1116137T1 (pt)
DK (1) DK1423138T3 (pt)
EA (1) EA006745B1 (pt)
ES (1) ES2533253T3 (pt)
HK (1) HK1069780A1 (pt)
HR (1) HRP20040071B1 (pt)
HU (1) HU230377B1 (pt)
IL (2) IL160230A0 (pt)
ME (1) ME00547B (pt)
MX (1) MXPA04001230A (pt)
NO (1) NO335688B1 (pt)
PL (1) PL227130B1 (pt)
PT (1) PT1423138E (pt)
RS (1) RS52224B (pt)
SI (1) SI1423138T1 (pt)
UA (1) UA78516C2 (pt)
WO (1) WO2003013577A2 (pt)
ZA (1) ZA200400442B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5069000B2 (ja) * 2004-06-30 2012-11-07 敦生 関山 非炎症性ストレス応答の指標剤およびその利用
DK1885753T3 (da) 2005-06-03 2011-10-03 Ares Trading Sa Fremstilling af rekombinant II-18-proteiner
DK1891088T3 (da) 2005-06-10 2012-01-30 Ares Trading Sa Fremgangsmåde til rensning af et IL-18-bindende protein
MY157173A (en) 2006-05-25 2016-05-13 Glaxo Group Ltd Modified humanised anti-interleukin-18
CN103458904B (zh) * 2010-12-16 2016-09-28 株式会社明治 格氏乳杆菌的菌体级分在制造用于减轻迟发型变态反应的组合物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE69925581T2 (de) * 1998-03-09 2006-04-27 Vertex Pharmaceuticals Inc., Cambridge 1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
KR100537558B1 (ko) * 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인터류킨-18 결합 단백질
AU5282600A (en) * 1999-05-20 2000-12-12 Hyseq, Inc. Interleukin-1 hy2 materials and methods
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
HU230377B1 (hu) 2016-03-29
ME00547B (me) 2011-12-20
US20040247598A1 (en) 2004-12-09
PT1423138E (pt) 2015-02-09
EP1423138B1 (en) 2014-12-24
RS52224B (sr) 2012-10-31
HRP20040071A2 (en) 2004-10-31
IL160230A (en) 2014-11-30
NO335688B1 (no) 2015-01-19
CN1568193A (zh) 2005-01-19
BRPI0211827B8 (pt) 2021-05-25
PL227130B1 (pl) 2017-10-31
HUP0401323A3 (en) 2006-01-30
YU11904A (sh) 2006-08-17
CN100500210C (zh) 2009-06-17
EA200400296A1 (ru) 2004-06-24
HRP20040071B1 (hr) 2015-08-28
AU2002331376B2 (en) 2007-06-14
WO2003013577A2 (en) 2003-02-20
WO2003013577A3 (en) 2003-09-25
CA2456247C (en) 2013-09-10
HUP0401323A2 (hu) 2004-10-28
JP2005501080A (ja) 2005-01-13
ZA200400442B (en) 2005-03-30
BRPI0211827B1 (pt) 2019-07-23
DK1423138T3 (en) 2015-02-23
EA006745B1 (ru) 2006-04-28
NO20040370L (no) 2004-03-23
UA78516C2 (en) 2007-04-10
PL368231A1 (en) 2005-03-21
EP1423138A2 (en) 2004-06-02
HK1069780A1 (en) 2005-06-03
CA2456247A1 (en) 2003-02-20
ES2533253T3 (es) 2015-04-08
SI1423138T1 (sl) 2015-04-30
MXPA04001230A (es) 2004-05-27
IL160230A0 (en) 2004-07-25
AR035274A1 (es) 2004-05-05
CY1116137T1 (el) 2017-02-08
KR20040030948A (ko) 2004-04-09
JP4301942B2 (ja) 2009-07-22

Similar Documents

Publication Publication Date Title
BR9911666A (pt) Combinação farmacêutica, uso da combinação, processo para tratamento de uma doença inflamatória em uma pessoa sofrendo de ou susceptìvel a tal doença, e, composição farmacêutica
PT1181027E (pt) Composicao dietetica ou farmaceutica para utilizacao na prevencao ou tratamento de hiperoxaluria
BR0213358A (pt) Uso de flibanserina
BR0212374A (pt) Oxintomodulina para a prevenção ou para o tratamento do excesso de peso
BR0214705A (pt) Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit
BR0308663A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
BR9812753A (pt) Combinação farmacêutica, uso da mesma, processo para tratamento de uma doença inflamatória, e, composição farmacêutica
PT1313489E (pt) Composicoes farmaceuticas para o tratamento de mucosite, estomatite e sindroma de behcet
BRPI0407234A (pt) Heterociclos substituìdos
IT1302365B1 (it) Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali
BR0312165A (pt) Utilização da taurina para o tratamento da alopecia
BR0108514A (pt) Uso de inibidores de il-18
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
BRPI0412919A (pt) combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos
HRP20050579B1 (hr) Nove sinergistiäśne kombinacije koje sadrže roflumilast i formoterol
PT1414473E (pt) Composicoes de administracao oral para o tratamento de disturbios do couro cabeludo
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
BR0211827A (pt) Uso de inibidores de il-18 em distúrbios de hipersensibilidade
BR9911005A (pt) Uso de ozÈnio para a preparação de medicamentos para o tratamento de cáries dentárias
BR0115983A (pt) Uso de sarp-1 para o tratamento e/ou prevenção de escleroderma
BR0210007A (pt) Uso de inibidores de il-18 para tratamento ou prevenção de lesões do sistema nervoso central
BR0210910A (pt) Derivados de imidazotriazinonas e sua aplicação contra processos inflamatórios e/ou doenças imunes
BR0111785A (pt) Composições e métodos para tratamento de candidìase
NO20003866D0 (no) Urte-antiviralt middel

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LABORATOIRES SERONO S.A. (CH)

Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SERONO S.A. (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/08/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 01/08/2022